Giuseppe Cullaro1, Meyeon Park2, Jennifer C Lai1. 1. Department of Medicine, Division of Gastroenterology and Hepatology, University of California-San Francisco, San Francisco, CA. 2. Department of Medicine, Division of Nephrology, University of California-San Francisco, San Francisco, CA.
Abstract
Acute kidney injury (AKI) is a critical determinant of outcomes in hospitalized patients with cirrhosis, but little is known of the impact of AKI in the outpatient setting. We analyzed 385 adult outpatients with cirrhosis listed for liver transplant at a single center; excluded were those with severe hepatic encephalopathy, with hepatocellular carcinoma, or on hemodialysis. Baseline serum creatinine (bCr) was defined as the lowest value recorded, peak Cr as the highest value, ΔCr as peak Cr minus bCr, AKI as a rise in serum Cr (sCr) by ≥0.3 mg/dL from bCr, persistent kidney injury as elevation of sCR by ≥0.3 mg/dL from bCr on each subsequent clinical assessment. Among 385 outpatients with cirrhosis, bCr was ≤0.70, 0.70-0.97, and ≥0.97 mg/dL in 28%, 38%, and 34%, respectively. At a median follow-up of 16 (range 8-28) months, 143 (37%) had one or more AKI episode, which increased significantly by bCr group (24% versus 37% versus 48%, P = 0.001). Of these 143 with AKI, 13% developed persistent kidney injury. A multivariable Cox regression analysis highlighted that bCr (hazard ratio [HR], 2.96) and ΔCr (HR, 2.05) were the only factors independently associated with the development of persistent kidney injury (P < 0.001). The likelihood of death/delisting increased by bCr group (14% versus 19% versus 28%, P = 0.03). A competing risk analysis demonstrated that each 1 mg/dL increase in bCr was independently associated with a 62% higher risk of death/delisting when accounting for transplantation and adjusting for confounders. Conclusion: AKI is not only common in outpatients with cirrhosis but even "clinically normal" bCr levels significantly impact the risk of persistent kidney injury and waitlist mortality, supporting the need for a lower clinical threshold to initiate monitoring of renal function and implementation of kidney-protective strategies.
Acute kidney injury (AKI) is a critical determinant of outcomes in hospitalized patients with cirrhosis, but little is known of the impact of AKI in the outpatient setting. We analyzed 385 adult outpatients with cirrhosis listed for liver transplant at a single center; excluded were those with severehepatic encephalopathy, with hepatocellular carcinoma, or on hemodialysis. Baseline serum creatinine (bCr) was defined as the lowest value recorded, peak Cr as the highest value, ΔCr as peak Cr minus bCr, AKI as a rise in serum Cr (sCr) by ≥0.3 mg/dL from bCr, persistent kidney injury as elevation of sCR by ≥0.3 mg/dL from bCr on each subsequent clinical assessment. Among 385 outpatients with cirrhosis, bCr was ≤0.70, 0.70-0.97, and ≥0.97 mg/dL in 28%, 38%, and 34%, respectively. At a median follow-up of 16 (range 8-28) months, 143 (37%) had one or moreAKI episode, which increased significantly by bCr group (24% versus 37% versus 48%, P = 0.001). Of these 143 with AKI, 13% developed persistent kidney injury. A multivariable Coxregression analysis highlighted that bCr (hazard ratio [HR], 2.96) and ΔCr (HR, 2.05) were the only factors independently associated with the development of persistent kidney injury (P < 0.001). The likelihood of death/delisting increased by bCr group (14% versus 19% versus 28%, P = 0.03). A competing risk analysis demonstrated that each 1 mg/dL increase in bCr was independently associated with a 62% higher risk of death/delisting when accounting for transplantation and adjusting for confounders. Conclusion:AKI is not only common in outpatients with cirrhosis but even "clinically normal" bCr levels significantly impact the risk of persistent kidney injury and waitlist mortality, supporting the need for a lower clinical threshold to initiate monitoring of renal function and implementation of kidney-protective strategies.
Authors: Paolo Angeli; Pere Ginès; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao Journal: J Hepatol Date: 2015-01-28 Impact factor: 25.083
Authors: Jennifer C Lai; Kenneth E Covinsky; Jennifer L Dodge; W John Boscardin; Dorry L Segev; John P Roberts; Sandy Feng Journal: Hepatology Date: 2017-06-28 Impact factor: 17.425
Authors: Javier Fernández; Miquel Navasa; Ramón Planas; Silvia Montoliu; David Monfort; German Soriano; Carmen Vila; Alberto Pardo; Enrique Quintero; Victor Vargas; Jose Such; Pere Ginès; Vicente Arroyo Journal: Gastroenterology Date: 2007-07-03 Impact factor: 22.682
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Nikhilesh R Mazumder; Kofi Atiemo; Matthew Kappus; Giuseppe Cullaro; Matthew E Harinstein; Daniela Ladner; Elizabeth Verna; Jennifer Lai; Josh Levitsky Journal: Transplantation Date: 2020-02 Impact factor: 5.385
Authors: Jasmohan S Bajaj; Guadalupe Garcia-Tsao; K Rajender Reddy; Jacqueline G O'Leary; Hugo E Vargas; Jennifer C Lai; Patrick S Kamath; Puneeta Tandon; Ram M Subramanian; Paul Thuluvath; Andrew Fagan; Tejasav Sehrawat; Randolph de la Rosa Rodriguez; Leroy R Thacker; Florence Wong Journal: Hepatology Date: 2021-07-08 Impact factor: 17.298
Authors: Jingqiao Zhang; Jie Liu; Yunhai Wu; Fernando Gomes Romeiro; Giovanni Battista Levi Sandri; Xinmiao Zhou; Miaomiao Li; Xingshun Qi Journal: Ann Transl Med Date: 2020-03
Authors: Giuseppe Cullaro; Jessica B Rubin; Brett E Fortune; Carl V Crawford; Elizabeth C Verna; Chi-Yuan Hsu; Kathleen D Liu; Robert S Brown; Jennifer C Lai; Russell Rosenblatt Journal: Dig Dis Sci Date: 2021-07-22 Impact factor: 3.487